Recent developments highlight Palvella’s clinical and regulatory progress with QTORIN Rapamycin, pipeline expansion, and financial activities supporting late-stage development.

• Palvella Therapeutics is preparing for the launch of QTORIN Rapamycin as its rare-disease pipeline expands [N1].
• The company received FDA priority review designation for QTORIN Rapamycin, with a decision expected in February 2027 [N1].
• Palvella completed a rolling NDA submission for QTORIN Rapamycin in microcystic lymphatic malformations and met Phase 3 study goals [N6].
• Additional FDA funding was secured to support QTORIN Rapamycin development in lymphatic malformations [N6].
• The company completed a $200 million upsized offering to advance its late-stage QTORIN pipeline [N8].
• Palvella reported Q2 2026 earnings with detailed call transcripts and highlights available [N4][N5].
• The rare-disease pipeline expansion and regulatory milestones have been noted by multiple analysts and coverage initiations [N7][N8].
• The company’s stock experienced significant gains in 2025 and early 2026, with insider transactions reported [N7].

Palvella’s advancement of QTORIN Rapamycin through Phase 3 clinical trials and receipt of FDA priority review designation demonstrate progress in addressing unmet medical needs in rare diseases. The company’s expanded pipeline and additional FDA funding support its development efforts. Strong liquidity from recent capital raises provides resources to sustain clinical programs. Positive clinical data and regulatory milestones enhance visibility into potential future commercialization opportunities in rare disease markets with limited treatment options.

Palvella remains a clinical-stage company with no approved products generating revenue, resulting in ongoing net losses and reliance on capital markets for funding. Regulatory approval risks persist for QTORIN Rapamycin and other pipeline candidates. The niche rare disease focus limits market size and may pose challenges for commercial scale. Potential delays or failures in clinical development or regulatory review could impact business prospects. Insider trading plans and share sales may introduce market perception risks.

Palvella Therapeutics’ moat derives from its focus on rare diseases with no FDA-approved therapies, creating high barriers to entry due to specialized clinical development and regulatory pathways. Its lead candidate, QTORIN Rapamycin, benefits from FDA priority review and orphan drug designations, which can provide market exclusivity and regulatory advantages. The company’s late-stage clinical progress and targeted pipeline expansion in underserved rare disease markets contribute to its competitive positioning. However, the moat is contingent on successful regulatory approvals and commercialization in niche indications with limited competition.

• Regulatory Approval Risk: Palvella’s lead candidate QTORIN Rapamycin is under FDA review but has not yet received approval, posing risk to future commercialization.
• Clinical Development Risk: Failure to meet clinical endpoints or unexpected safety issues in ongoing or future trials could delay or halt product development.
• Financial Risk: The company reports net losses and depends on capital raises to fund operations, which may dilute shareholders or limit resources.
• Market Risk: Focus on rare diseases limits market size and may affect revenue potential and commercial viability.
• Insider Trading and Market Perception Risk: Trading plans and insider sales could influence investor sentiment and stock price volatility.

• Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies.
• The company is advancing a late clinical-stage pipeline and platform targeting multiple rare diseases.
• Its lead product candidate is QTORIN Rapamycin, which is under a rolling NDA review by the FDA for treatment of microcystic lymphatic malformations.
• Palvella has received FDA priority review designation for QTORIN Rapamycin, with a decision anticipated in February 2027.
• The company completed a Phase 3 study (SELVA) for QTORIN Rapamycin in microcystic lymphatic malformations, meeting its study goals.
• Palvella has received additional FDA funding to support QTORIN Rapamycin development in lymphatic malformations.
• The company has expanded its rare-disease pipeline beyond QTORIN Rapamycin.
• Palvella completed a $200 million upsized offering to advance its late-stage QTORIN pipeline.
• As of September 30, 2026, Palvella reported cash and cash equivalents of $193.3 million and short-term investments of $43.4 million, with total current assets of $239.0 million and current liabilities of $14.9 million, resulting in a strong current ratio of 16.01 and cash ratio of 15.85.
• For the quarter ended September 30, 2026, the company reported a net loss of $24.6 million and basic and diluted EPS of -$1.70 per share.
• There have been no material changes in risk factors since the 2025 Form 10-K filing.
• The company’s officers and directors may adopt Rule 10b5-1 trading plans for securities transactions, with no unusual insider trading activity reported in the latest quarter.